A Phase 3 interventional study of Felzartamab and Placebo in Antibody-mediated Rejection, sponsored by Biogen. Active, not recruiting at 56 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by Biogen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In this study, researchers will learn more about the use of felzartamab in kidney transplant patients who have antibody-mediated rejection, also known as AMR. Kidney transplants can save lives for people with kidney failure. But even after a successful transplant, the body's immune system can sometimes attack the new kidney.
Antibody-mediated rejection (AMR) is when a person's immune system attacks a transplanted organ, like a new kidney. In the person receiving the transplant, their immune system creates specific antibodies. Antibodies are proteins that help the body fight infections. In people with AMR, these antibodies mistakenly see the new organ as a threat and damage its blood vessels. This can cause the new organ to fail.
In this study, researchers will learn more about how a study drug called felzartamab affects people with AMR. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce antibodies, helping to lower their buildup in the kidneys. The main goal of this study is to compare how felzartamab works in participants with kidney transplants who experience AMR compared to a placebo. A placebo is something that looks like the study drug but does not contain any medicine. A placebo is also given in the same way as the study drug. All participants in this study will have active AMR or AMR that has lasted for at least 6 months after their kidney transplant.
The main question that researchers want to answer is:
Researchers will also learn about:
The study will be done as follows:
The primary objective of this study is to evaluate the efficacy of felzartamab compared to placebo in kidney transplant recipients diagnosed with active or chronic active AMR.
The secondary objectives of this study are: Part A: To evaluate the efficacy of felzartamab compared to placebo through additional clinical endpoints; Part B: To summarize felzartamab efficacy at Week 52 in kidney transplant recipients diagnosed with active or chronic active AMR; Parts A and B: To evaluate the safety of felzartamab in kidney transplant recipients diagnosed with active or chronic AMR and to assess the pharmacokinetic (PK) profile and immunogenicity of felzartamab.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Treatment: Prior AMR/TCMR treatment (with the exception of ) within 3 months prior to randomization is excluded as listed below. Participants who received any of these treatments between 3 and 6 months prior to randomization must have both a renal biopsy (IC3) and DSA testing at least 6 weeks after completing (or stopping) treatment in order to confirm continuing AMR and to determine eligibility:
Note: Other protocol-defined inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Felzartamab
Drug: Placebo
Participants will receive felzartamab by intravenous infusion.
Also known as: MOR202, MOR03087, TJ202, HIB202, BIIB148
Participants will receive 0.9% saline solution by intravenous infusion.
Part A: Percentage of Participants Who Achieve Biopsy-proven Histologic Resolution (BPHR)
Time frame: Week 24
Part A: Microvascular Inflammation (MVI) Score
Time frame: Week 24
Part A: Percentage of Participants Who Achieve an MVI Score of 0
Time frame: Week 24
Part A: Change from Baseline in Donor-derived Cell-free DNA (dd-cfDNA)
Time frame: Baseline, Week 24
Part A: Biopsy-based Transcript Composite Score for AMR/MVI
Time frame: At Week 24
Part A: Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Time frame: Baseline, Week 24
Part B: Percentage of Participants Who Achieve BPHR
Time frame: Weeks 24 and 52
Part B: MVI Score
Time frame: Weeks 24 and 52
Part B: Percentage of Participants Who Achieve an MVI Score of 0
Time frame: Weeks 24 and 52
Part B: Change from Baseline in dd-cfDNA
Time frame: Baseline, Weeks 24 and 52
Part B: Biopsy-based Transcript Composite Score for AMR/MVI
Time frame: At Week 52
Part B: Change from Baseline in eGFR
Time frame: Baseline, Weeks 24 and 52
Part B: Time to All-cause Allograft Loss
Time frame: Up to Week 52
Parts A and B: Number of Participants with Adverse Events
Time frame: From time of first dose to end of trial visit (Up to Week 52)
Parts A and B: Number of Participants with Clinically Significant Laboratory Abnormalities
Time frame: From time of first dose to end of trial visit (Up to Week 52)
Parts A and B: Number of Participants with Clinically Significant Vital Signs Abnormalities
Time frame: From time of first dose to end of trial visit (Up to Week 52)
Parts A and B: Number of Participants with Clinically Significant ECG Abnormalities
Time frame: From time of first dose to end of trial visit (Up to Week 52)
Parts A and B: Percentage of Participants with T Cell-mediated Rejection (TCMR) by Biopsy
Time frame: Weeks 24 and 52
Parts A and B: Felzartamab Serum Concentration
Time frame: Up to Week 52
Parts A and B: Number of Participants with Anti-drug Antibodies (ADAs) against Felzartamab
Time frame: Baseline, up to Week 52
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Felzartamab